Pharmaceutical With the aim of curbing diversion and misuse, the US Drug Enforcement Administration (DEA) is proposing to reduce the amount of five Schedule II opioid controlled substances that can be manufactured in the United States next year compared with 2019, per the Notice of Proposed Rulemaking being published in the Federal Register and available for public inspection here. 12 September 2019